The new multivalent vaccine, manufactured for the clinical trial in MIRC’s Robert E. Fitzhenry Vector Laboratory, targets multiple viral proteins, both the spike protein on the surface and proteins inside the virus.
Read more at Originally published on Brighter World.
McMaster Immunology Research Centre, News, ResearchRelated News
News Listing
Two Faculty of Health Sciences cancer researchers awarded Canada Research Chairs
Dept. Biochem, Dept. Surgery, Feature, Research
6 days ago
Elena Verdu appointed director of Farncombe Family Digestive Health Research Institute
Faculty & Staff, Research
6 days ago